The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:
Lv X; Wang H; Chen C; Zhao Y; Li K and 4 more

Journal:
Diabetes Metab Syndr Obes

Publication Year: 2024

DOI:
10.2147/DMSO.S443396

PMCID:
PMC10873148

PMID:
38371390

Journal Information

Full Title: Diabetes Metab Syndr Obes

Abbreviation: Diabetes Metab Syndr Obes

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology & Metabolism

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The manuscript has no financial relationship with any institution and all authors claim no conflict of interest."

Evidence found in paper:

"This study was funded by the National Natural Science Foundation of China (No.81960155), Natural Science Foundation of Gansu Province (20JR10RA690) and The Hospital Fund of the First Hospital of Lanzhou University (ldyy-2021-01)."

Evidence found in paper:

"The PubMed, Embase, Cochrane Library and Web of Science databases were systematically searched from their inception until December 2022 for literature on TZP treatment for overweight/obese T2DM patients. The literature search included the following keywords: Type 2 diabetes mellitus, Tirzepatide, body weight, lipids, blood pressure, and others. The selected studies were presented and reported in accordance with the PRISMA-P System Evaluation Reporting Guidelines. Predefined schemes were registered with PROSPERO under the registration number CRD42022370543."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025